The GI Research Department seeks patients 18 to 75 years old with mild to moderate ulcerative colitis (UC) for a research study. The COLLECTiVE202 study is testing an investigational drug product called VE202, which is designed to rebalance the bacteria in your intestine and, when used in combination with your other UC treatment, return your intestinal tract to a healthier state.
To take part in the study, you must meet the following basic requirements:
• Be 18 to 75 years old
• Have mild to moderate UC that was diagnosed at least 3 months before joining the study
• Have not taken a biologic drug for your ulcerative colitis in the past
• Do not have Crohn’s disease, indeterminate colitis, or primary sclerosing cholangitis (swelling and scarring of the liver’s bile ducts)
• Do not have a known allergy to vancomycin
Study involves taking an experimental medicine/placebo, blood draws, electronic diary completion and colonoscopy. This study will be divided into 3 parts. If you qualify for the study and agree to join, you will be expected to be involved in all 3 study parts. Your participation in the study is expected to end in about 56 weeks (just over a year). Screening may take up to 4 weeks, Part 1 is 8 weeks, Part 2 is 8 weeks, and Part 3 is 36 weeks.
It is not expected to cost you anything to participate in the study. The study-related medications will be provided
at no charge to you, and you will not be charged for any visits or procedures performed for this study. You may
also be reimbursed for reasonable expenses such as your travel costs for attending the study visits.
$1250